Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [11] Results of a phase 2, multicenter, single-arm study of eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer
    Vandat, L.
    Schwartzberg, L.
    Gluck, S.
    Rege, J.
    Liao, J.
    Cox, D.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
  • [12] Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer
    Wilks, Sharon
    Puhalla, Shannon
    O'Shaughnessy, Joyce
    Schwartzberg, Lee
    Berrak, Erhan
    Song, James
    Cox, David
    Vandat, Linda
    CLINICAL BREAST CANCER, 2014, 14 (06) : 405 - 412
  • [13] Eribulin mesylate as first-line therapy for locally recurrent or metastatic HER2-negative breast cancer: Results of a phase 2, multicenter, single-arm study
    Mcintyre, K.
    O'Shaughnessy, J.
    Schwartzberg, L.
    Glueck, S.
    Berrak, E.
    Song, J.
    Rege, J.
    Cox, D.
    Vahdat, L.
    CANCER RESEARCH, 2013, 73
  • [14] A phase II, multicenter, single-arm trial of eribulin as first or second line chemotherapy for HER2-negative advanced or metastatic breast cancer: Evaluation of efficacy, safety, and patient-reported outcomes.
    Iwamoto, Mitsuhiko
    Kimura, Kosei
    Tanaka, Satoru
    Yamamoto, Daigo
    Yoshidome, Katsuhide
    Ogura, Hiroyuki
    Terasawa, Risa
    Matsunami, Nobuki
    Takahashi, Yuko
    Nitta, Toshikatsu
    Morimoto, Takashi
    Fujioka, Hiroya
    Kawaguchi, Kanako
    Uchiyama, Kazuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [15] A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent
    Christos Fountzilas
    Ravi Chhatrala
    Nikhil Khushalani
    Wei Tan
    Charles LeVea
    Alan Hutson
    Chris Tucker
    Wen Wee Ma
    Graham Warren
    Patrick Boland
    Renuka Iyer
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 497 - 505
  • [16] A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent
    Fountzilas, Christos
    Chhatrala, Ravi
    Khushalani, Nikhil
    Tan, Wei
    LeVea, Charles
    Hutson, Alan
    Tucker, Chris
    Ma, Wen Wee
    Warren, Graham
    Boland, Patrick
    Iyer, Renuka
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) : 497 - 505
  • [17] Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).
    Liu, Minetta C.
    Hillman, David W.
    Frith, Ashley Elizabeth
    Lyss, Alan P.
    Weckstein, Douglas Jay
    Moreno-Aspitia, Alvaro
    Le-Lindqwister, Nguyet
    Isaacs, Claudine
    Wender, Donald B.
    Lewis, DeQuincy Andrew
    Cole, John T.
    Jaslowski, Anthony John
    Rowland, Kendrith M.
    Openshaw, Thomas H.
    Friday, Bret Edward Buckley
    Fleming, Gini F.
    Asmus, Erik
    Rogak, Lauren J.
    Basch, Ethan M.
    Dueck, Amylou C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [18] Phase 2, multicenter, single-arm study of eribulin mesylate plus trastuzumab as first-line therapy for locally recurrent or metastatic HER2-positive breast cancer
    Wilks, S.
    Puhalla, S.
    O'Shaughnessy, J.
    Schwartzberg, L.
    Berrak, E.
    Song, J.
    Rege, J.
    Cox, D.
    Vahdat, L.
    CANCER RESEARCH, 2013, 73
  • [19] Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial
    Ahn, Daniel H.
    Ridinger, Maya
    Cannon, Timothy L.
    Mendelsohn, Lawrence
    Starr, Jason S.
    Hubbard, Joleen M.
    Kasi, Anup
    Barzi, Afsaneh
    Samuelsz, Errin
    Karki, Anju
    Subramanian, Ramanand A.
    Yemane, Divora
    Kim, Roy
    Wu, Chu-Chiao
    Croucher, Peter J. P.
    Smeal, Tod
    Kabbinavar, Fairooz F.
    Lenz, Heinz-Josef
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [20] Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer
    Borner, MM
    Dietrich, D
    Stupp, R
    Moran, R
    Honegger, H
    Wernli, M
    Herrmann, R
    Pestalozzi, BC
    Saletti, P
    Hanselmann, S
    Müller, S
    Brauchli, P
    Castiglione-Gertsch, M
    Goldhirsch, A
    Roth, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) : 1759 - 1766
12345